rs137853247
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 1P and 9B. BA1BS3_SupportingPM1_Supporting
This summary comes from the ClinGen Evidence Repository: The c.92G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of glycine to aspartic acid at codon 31 (p.(Gly31Asp)) of NM_000545.8. This variant is located within the dimerization domain (codons 1-32) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). While it has been noted to be a pathogenic variant in the literature, there are numerous pieces of evidence that refute this classification. Functional studies demonstrated the p.Gly31Asp protein has DNA binding above 75% of wild type, indicating that this variant does not impact protein function (PMID:32910913) (BS3_Supporting). This variant has a REVEL score of 0.591, which is between the ClinGen MDEP thresholds predicting neither a damaging nor benign impact on HNF1A function. The variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.000772 (0.0772%), which is greater than the MDEP threshold for BA1 (≥0.0001) (BA1). It has been was identified in >30 unrelated individuals with diabetes; however, PS4 cannot be applied because the variant MAF in gnomAD is above the ClinGen MDEP PM2_Supporting cutoff (PMID:31365591, 31638168, 19169489, 26431509, 28395978, 20950394, 26059258, 19929997, 22432108, 27899486, 23551881, 24041679, 16917892, 21696527, and others). In summary, c.92G>A meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 6/4/2021): BA1, BS3_Supporting, PM1_Supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA124487/MONDO:0015967/017
Frequency
Consequence
NM_000545.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HNF1A | NM_000545.8 | c.92G>A | p.Gly31Asp | missense_variant | 1/10 | ENST00000257555.11 | NP_000536.6 | |
HNF1A | NM_001306179.2 | c.92G>A | p.Gly31Asp | missense_variant | 1/10 | NP_001293108.2 | ||
HNF1A | NM_001406915.1 | c.92G>A | p.Gly31Asp | missense_variant | 1/9 | NP_001393844.1 | ||
HNF1A | XM_024449168.2 | c.92G>A | p.Gly31Asp | missense_variant | 1/9 | XP_024304936.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HNF1A | ENST00000257555.11 | c.92G>A | p.Gly31Asp | missense_variant | 1/10 | 1 | NM_000545.8 | ENSP00000257555.5 |
Frequencies
GnomAD3 genomes AF: 0.000782 AC: 119AN: 152178Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000772 AC: 192AN: 248682Hom.: 1 AF XY: 0.000703 AC XY: 95AN XY: 135122
GnomAD4 exome AF: 0.000888 AC: 1298AN: 1461178Hom.: 3 Cov.: 35 AF XY: 0.000860 AC XY: 625AN XY: 726922
GnomAD4 genome AF: 0.000781 AC: 119AN: 152296Hom.: 0 Cov.: 32 AF XY: 0.000765 AC XY: 57AN XY: 74478
ClinVar
Submissions by phenotype
not specified Uncertain:1Benign:3
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Mar 26, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Nov 16, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 13, 2024 | Variant summary: HNF1A c.92G>A (p.Gly31Asp) results in a non-conservative amino acid change located in the HNF-1, dimerization domain (IPR044866) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00088 in 1613474 control chromosomes, predominantly at a frequency of 0.0017 within the Latino subpopulation in the gnomAD database, including 1 homozygote. The observed variant frequency within Latino control individuals in the gnomAD database is approximately 68 fold of the estimated maximal expected allele frequency for a pathogenic variant in HNF1A causing Maturity Onset Diabetes Of The Young 3 phenotype (2.5e-05). c.92G>A has been reported in the literature in individuals affected with HNF1A-related conditions (examples: Urruitia_2019, Johnson_2019). These report(s) do not provide unequivocal conclusions about association of the variant with Maturity Onset Diabetes of The Young 3. At least one publication reports experimental evidence evaluating an impact on protein function. These results showed no damaging effect of this variant. The following publications have been ascertained in the context of this evaluation (PMID: 32910913, 31365591, 30191644). ClinVar contains an entry for this variant (Variation ID: 14948). Based on the evidence outlined above, the variant was classified as benign. - |
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 06, 2020 | The p.Gly31Asp variant in HNF1A is classified as likely benign because it has also been identified in 0.16% (55/35352) of Latino chromosomes by gnomAD (http://gnomad.broadinstitute.org; dbSNP rs137853247). This variant has also been reported in ClinVar (Variation ID 29987). Computational prediction tools and conservation analysis do not provide strong support for or against an impact to the protein. ACMG/AMP criteria applied: BS1. - |
not provided Uncertain:1Benign:3
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 01, 2017 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | HNF1A: BS1, BS2 - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 26, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 26, 2019 | - - |
Maturity-onset diabetes of the young type 3 Pathogenic:1Benign:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2005 | - - |
Benign, criteria provided, single submitter | clinical testing | Mendelics | Aug 22, 2023 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Maturity onset diabetes mellitus in young Pathogenic:1Benign:1
Likely pathogenic, criteria provided, single submitter | research | Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic | - | Mutations in HNF1A gene can predispose to MODY3. It is associated with both micro and macrovascular complications of diabetes, especially cardiovascular complications. Associated with glucosuria. May respond well to sulfonylureas. Sufficient evidence is found to confer the association of this particular variant rs137853247 with MODY3. - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 15, 2022 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Clear cell carcinoma of kidney Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2005 | - - |
Chromophobe renal cell carcinoma Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2005 | - - |
HNF1A-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 28, 2024 | The HNF1A c.92G>A variant is predicted to result in the amino acid substitution p.Gly31Asp. This variant has been repeatedly reported in patients with maturity onset diabetes of the young (MODY), but its pathogenicity is still inconclusive (Chèvre et al. 1998. PubMed ID: 9754819; Beijers et al. 2009. PubMed ID: 19929997; Thanabalasingham et al. 2012. PubMed ID: 22432108). This variant could be pathogenic but a decreased penetrance may occur (Thanabalasingham et al. 2012. PubMed ID: 22432108). This variant is reported in 0.16% of alleles in individuals of Latino descent in gnomAD, including one homozygous observation. Of note, at PreventionGenetics, the HNF1A c.92G>A (p.Gly31Asp) variant has been observed in an individual with MODY heterozygous for a pathogenic GCK variant. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Diabetes mellitus type 1;C0011860:Type 2 diabetes mellitus;C1838100:Maturity-onset diabetes of the young type 3;C1840646:Hepatic adenomas, familial;C2675866:Type 1 diabetes mellitus 20;CN074294:Nonpapillary renal cell carcinoma Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 24, 2021 | - - |
Monogenic diabetes Benign:1
Benign, reviewed by expert panel | curation | ClinGen Monogenic Diabetes Variant Curation Expert Panel | Dec 15, 2021 | The c.92G>A variant in the HNF1 homeobox A gene, HNF1A, causes an amino acid change of glycine to aspartic acid at codon 31 (p.(Gly31Asp)) of NM_000545.8. This variant is located within the dimerization domain (codons 1-32) of HNF1A, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1_Supporting). While it has been noted to be a pathogenic variant in the literature, there are numerous pieces of evidence that refute this classification. Functional studies demonstrated the p.Gly31Asp protein has DNA binding above 75% of wild type, indicating that this variant does not impact protein function (PMID: 32910913) (BS3_Supporting). This variant has a REVEL score of 0.591, which is between the ClinGen MDEP thresholds predicting neither a damaging nor benign impact on HNF1A function. The variant has a Popmax Filtering allele frequency in gnomAD 2.1.1 of 0.000772 (0.0772%), which is greater than the MDEP threshold for BA1 (≥0.0001) (BA1). It has been was identified in >30 unrelated individuals with diabetes; however, PS4 cannot be applied because the variant MAF in gnomAD is above the ClinGen MDEP PM2_Supporting cutoff (PMID: 31365591, 31638168, 19169489, 26431509, 28395978, 20950394, 26059258, 19929997, 22432108, 27899486, 23551881, 24041679, 16917892, 21696527, and others). In summary, c.92G>A meets the criteria to be classified as benign for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.1, approved 6/4/2021): BA1, BS3_Supporting, PM1_Supporting. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at